| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 Feb 2026 | 19 Feb 2026 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/02/2026 inter alia to consider and approve the Audited Financial Results and Statements for the Quarter and Financial Year ended 31st December 2025 and Recommendation of Final Dividend if any. Please find enclosed outcome of the Borad meeting for: 1. Audited Financial Results and Statements for the Quarter and Financial Year ended 31st December 2025. 2. Final dividend of Rs. 48 per equity share of the face value of Rs. 10 each for the Financial Year ended 31st December 2025, subject to the approval of Shareholders 3. Change in Directors (As Per BSE Announcement Dated on:25.02.2026) | ||
| Board Meeting | 29 Oct 2025 | 23 Oct 2025 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2025 ,inter alia, to consider and approve the Unaudited Financial Statements for the Quarter and Nine-months ended 30th September 2025 and Declaration of Interim Dividend for the year 2025, if any. Please find enclosed outcome of the Board Meeting held on 29th October 2025. (As Per BSE Announcement Dated On : 29.10.2025) | ||
| Board Meeting | 27 Oct 2025 | 27 Oct 2025 |
| Outcome of Board Meeting of the Company held on Monday, 27th October 2025 | ||
| Board Meeting | 25 Sep 2025 | 25 Sep 2025 |
| Please find enclosed intimation regarding resignation of the Company Secretary and Compliance Officer. | ||
| Board Meeting | 31 Jul 2025 | 18 Jul 2025 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2025 inter alia to consider and approve the Unaudited Financial Statements for the quarter and half-year ended 30th June 2025. We have enclosed a copy of Financial Results for the Quarter and Half-year ended 30th June 2025. (As Per BSE Announcement Dated on: 31/07/2025) | ||
| Board Meeting | 16 Jul 2025 | 16 Jul 2025 |
| Please find enclosed Outcome of Board Meeting dated 16th July 2025. | ||
| Board Meeting | 14 May 2025 | 9 May 2025 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 inter alia to consider and approve the Unaudited Financial Statements for the Quarter ended 31st March 2025 Please find enclosed a copy of the Unaudited Financial Results for the Quarter ended 31st March 2025 (As Per BSE Announcement Dated on: 14/05/2025) | ||
| Board Meeting | 18 Mar 2025 | 18 Mar 2025 |
| The Board has approved the re-appointment of Mr. Rahul Bhatnagar as an Independent Director of the Company for a second term of five consecutive years, subject to the approval of the members at the ensuing AGM. | ||
The board has proposed a final dividend of ₹117 per equity share (face value of ₹10), subject to shareholders approval at the next Annual General Meeting.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
